Allergan receives 2016 ENERGY STAR Partner of the Year Award from US Environmental Protection Agency
Company recognized with ENERGY STAR Award for fifth time.
Allergan has received an ENERGY STAR 2016 Partner of the Year — Sustained Excellence Award from the US Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors.
Allergan has been an ENERGY STAR partner since 1996 and recognized by the EPA for the fifth time. The 2016 Partner of the Year — Sustained Excellence Awards are presented to organizations recognizing their contributions to reducing harmful carbon pollution through superior energy efficiency efforts. These awards recognize ongoing leadership in the ENERGY STAR program.
"By continued collaboration with ENERGY STAR, Allergan is helping Americans save money, save energy, and do their part to reduce our nation's greenhouse gas emissions that exacerbate climate change," said EPA Administrator Gina McCarthy. "I'm proud to recognize Allergan with the highest form of ENERGY STAR recognition, as the winner of the 2016 Partner of the Year — Sustained Excellence Award. Allergan demonstrates a strong commitment to energy efficiency and to preserving a healthy planet for future generations."
The award also recognizes four Allergan manufacturing sites that have achieved ENERGY STAR rankings in the top 25% of pharmaceutical plant energy performance nationwide: Waco, Texas for eight consecutive years, and first time awards for Cincinnati, Ohio; Fajardo, Puerto Rico; and Manati, Puerto Rico. Also achieving ENERGY STAR certification this year were five buildings at the Allergan campus in Irvine, CA.
"Allergan has a long history and commitment to improving our energy performance and reducing our impact on the environment, and we are proud to be recognized by ENERGY STAR for our efforts," said Wayne Swanton, Senior Vice President, Global Operations at Allergan. "Our partnership with ENERGY STAR is part of our ongoing commitment to the environment, including using greener sources of energy and reducing greenhouse gas emissions within our operations."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.